Does Oscar Health Cover Prolia?

How Oscar Health Classifies Prolia

Oscar Health plans sold on ACA marketplaces and through employer groups follow a formulary structure that places medications into tiers. Prolia, a biologic monoclonal antibody targeting RANKL, is classified as a specialty medication on most Oscar formularies. That specialty designation affects cost-sharing.

Pharmacy Benefit vs. Medical Benefit

Because Prolia is administered by injection in a healthcare provider's office, it can be billed under either the pharmacy benefit or the medical benefit. Oscar plans frequently process provider-administered injectables under the medical benefit (Part B-style billing), which means your cost-sharing follows your plan's coinsurance percentage for outpatient services rather than a flat pharmacy copay. Ask your Oscar plan's member services team (the number on the back of your ID card) which benefit applies to your specific plan.

Metal Tier and Cost-Sharing

Oscar offers Bronze, Silver, Gold, and Platinum plans in most of its markets. A Bronze plan with 40% coinsurance on specialty drugs could leave you responsible for roughly $780 per injection at list price. A Gold or Platinum plan with 10% to 20% coinsurance brings that down to $195 to $390, though negotiated rates between Oscar and Amgen may lower the base price further. The Endocrine Society's 2020 clinical practice guideline recommends denosumab as a first-line option for postmenopausal women at high fracture risk, a classification that strengthens the medical necessity argument during prior authorization review.

Prior Authorization Requirements

Oscar Health requires prior authorization for Prolia on nearly every plan design. The insurer wants clinical documentation confirming that the patient meets FDA-approved criteria before it will approve payment.

What Oscar Typically Asks For

Your prescribing physician will need to submit a prior authorization form that includes: a confirmed diagnosis of osteoporosis via dual-energy X-ray absorptiometry (DXA) with a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip, or a history of fragility fracture. Oscar may also require documentation of intolerance or contraindication to oral bisphosphonates (alendronate, risedronate) before approving Prolia. The FREEDOM trial (N=7,868) demonstrated that denosumab reduced the risk of new vertebral fractures by 68% over 36 months compared with placebo [1], data your physician can cite in the authorization request.

Step Therapy Considerations

Some Oscar plans enforce step therapy, requiring a trial of at least one oral bisphosphonate before covering denosumab. If a patient has documented gastrointestinal intolerance, esophageal disorders, or inability to remain upright for 30 minutes post-dose, the step therapy requirement can be overridden. The American Association of Clinical Endocrinology (AACE) 2020 guideline positions denosumab as appropriate first-line therapy for patients at very high fracture risk (T-score <-3.0, recent fracture within 12 months, or fractures while on other osteoporosis therapy), which supports a step therapy exception.

Timeline for Approval

Oscar typically processes prior authorization decisions within 72 hours for non-urgent requests. Urgent requests (for example, a patient needing to continue therapy without a gap after switching from another insurer) may be decided within 24 hours. If denied, you have the right to an internal appeal and, if that fails, an external independent review.

What Prolia Costs on Oscar Health Plans

Out-of-pocket costs vary widely depending on the plan, whether you have met your deductible, and whether the drug is processed under the pharmacy or medical benefit.

Before You Meet Your Deductible

On most Oscar Bronze and Silver plans, you will pay the full negotiated cost of Prolia until your annual deductible is met. Oscar's negotiated rate for Prolia is not publicly disclosed but is typically 15% to 40% below the $1,950 list price. Once you meet your deductible, your plan's coinsurance kicks in.

After Deductible

A patient on a Silver plan with 30% coinsurance on specialty drugs, assuming a negotiated price of $1,400 per injection, would pay approximately $420 per dose. Over 12 months (two injections), that totals roughly $840 in coinsurance alone.

Out-of-Pocket Maximum Protection

All Oscar ACA-compliant plans cap annual out-of-pocket spending. For 2026, the federal out-of-pocket maximum is $9,200 for individual coverage. Once reached, Oscar covers 100% of in-network costs, including Prolia. Patients with high medication burdens may reach this cap within the first half of the year.

A study published in the Journal of Bone and Mineral Research (N=2,315) found that cost-related nonadherence to denosumab affected roughly 12% of commercially insured patients, with the highest rates among those on high-deductible health plans [2]. Reducing financial barriers directly affects fracture prevention outcomes.

How to Lower Your Prolia Costs With Oscar

Several strategies can reduce what you pay for denosumab, even on a high-deductible Oscar plan.

Amgen's FIRST STEP Program

Amgen offers the FIRST STEP copay assistance program for commercially insured patients, covering up to $1,500 per injection. Patients with Oscar insurance are eligible as long as they are not enrolled in a government-funded program (Medicare, Medicaid, TRICARE). The program effectively eliminates most or all copay and coinsurance for many patients. Enrollment is available at Amgen's support site or by calling the number on the Prolia prescribing information.

Ask About Medical Benefit Billing

If Prolia is billed under Oscar's medical benefit rather than the pharmacy benefit, the cost-sharing structure may differ. In some plan designs, the medical benefit coinsurance is lower than the specialty pharmacy copay. Your provider's billing department can run a benefit verification through Oscar to determine which route produces lower out-of-pocket costs.

Oscar's Virtual-First Model

Oscar Health emphasizes a virtual-first care model with dedicated care teams. Your Oscar care team can help coordinate prior authorization, check benefit details, and connect you with Amgen's patient assistance programs. Use the Oscar app to message your care team directly, which can speed up the authorization process compared with waiting for a phone callback.

Clinical Context: Why Prolia Coverage Matters

Prolia is not interchangeable with oral bisphosphonates for every patient. Understanding the clinical rationale helps when advocating for coverage.

Mechanism and Efficacy

Denosumab is a fully human monoclonal antibody that binds RANKL, blocking osteoclast formation and activity. The FREEDOM trial demonstrated a 68% reduction in vertebral fractures, 40% reduction in hip fractures, and 20% reduction in nonvertebral fractures over 3 years [1]. A 10-year extension of FREEDOM (N=4,550) showed sustained fracture risk reduction with continued therapy, and lumbar spine bone mineral density increased by 21.7% from baseline over the full treatment period [3].

Discontinuation Risk

One reason continuous coverage matters: stopping denosumab without transitioning to another antiresorptive causes rapid bone loss. A post hoc analysis published in the Journal of Bone and Mineral Research found that patients who discontinued denosumab without follow-on therapy experienced vertebral fracture rates of 7.1% within the first year off treatment, compared with 0.8% in those who continued [4]. The Endocrine Society and AACE both recommend against unsupervised discontinuation and advise transitioning to a bisphosphonate (typically zoledronic acid) after stopping denosumab.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "Denosumab discontinuation without a bridging agent is a clinical emergency waiting to happen. Insurers must ensure continuity of coverage to prevent rebound vertebral fractures" [5].

Who Benefits Most

The FDA label for Prolia includes three osteoporosis-related indications: postmenopausal women at high fracture risk, men with osteoporosis at high fracture risk, and patients receiving aromatase inhibitor or androgen deprivation therapy for cancer. Patients with renal impairment (eGFR <30 mL/min) who cannot use bisphosphonates have a particularly strong medical necessity case, since denosumab does not require renal dose adjustment [6].

Oscar Health's Formulary and Appeals Process

If Prolia is denied, Oscar provides a structured appeals pathway.

Checking the Formulary

Oscar publishes its formulary online for each plan year and state. Search for "denosumab" or "Prolia" in the Oscar formulary lookup tool available on oscar.com. The formulary will show tier placement, prior authorization requirements, quantity limits, and any step therapy restrictions. Formularies can change at the start of each plan year, so confirm coverage annually.

Filing an Appeal

If prior authorization is denied, your physician can file an internal appeal within 180 days of the denial. Include peer-reviewed evidence supporting medical necessity. The AACE guideline and FREEDOM trial data are strong supporting documents. If the internal appeal is denied, you can request an external review by an independent review organization (IRO) within your state. Under ACA rules, the IRO's decision is binding on Oscar.

Dr. Andrea Singer, Director of Women's Primary Care at MedStar Georgetown, has noted: "Payers who require step therapy through oral bisphosphonates before covering denosumab should reconsider for patients with very high fracture risk. AACE guidelines support denosumab as initial therapy in that population" [7].

Exceptions for Continuation of Therapy

If you are switching to Oscar from another insurer and are already established on Prolia, request a continuity of care exception. Oscar's transition of care policy typically allows a temporary supply (one injection cycle) while the new plan's prior authorization is processed.

Comparing Prolia Coverage Across Insurer Types

Oscar is a technology-focused insurer operating in the individual and small-group ACA markets. Coverage for specialty biologics like Prolia varies by insurer type.

Oscar vs. Traditional Carriers

Large national carriers (UnitedHealthcare, Aetna, Cigna) also cover Prolia with prior authorization. Oscar's cost-sharing structure is comparable to these carriers at equivalent metal tiers. Where Oscar differs is in its care coordination model: the dedicated care team approach may simplify the prior authorization process compared with navigating a traditional insurer's call center.

Medicare Advantage Considerations

Oscar also offers Medicare Advantage plans in select markets. Under Medicare Part B, Prolia administered in a physician's office is covered at 80% after the Part B deductible ($257 in 2026), leaving the patient responsible for roughly $390 per injection at the Medicare allowable rate. Oscar Medicare Advantage plans may offer different cost-sharing depending on plan design.

Market Availability

Oscar Health operates in 22 states as of 2026. If you are considering an Oscar plan specifically for Prolia coverage, verify that Oscar is available in your state and that your physician is in-network before enrolling during open enrollment.

Monitoring and Safety While on Prolia

Patients receiving Prolia on any insurance plan should be aware of required monitoring that insurers expect to see documented in the medical record.

Baseline and Ongoing Labs

The FDA prescribing information recommends checking serum calcium before each injection. Hypocalcemia must be corrected before administering denosumab. Patients should take calcium 1,000 mg daily and vitamin D 400 to 800 IU daily throughout treatment [6]. Oscar may audit these labs during utilization review for reauthorization.

DXA Scan Frequency

Most guidelines, including the ISCD 2019 position statement, recommend DXA monitoring every 1 to 2 years during antiresorptive therapy. Oscar covers DXA scans as preventive or diagnostic imaging; confirm your plan's specific coverage interval.

Duration of Therapy

There is no established maximum duration for denosumab therapy. The FREEDOM extension trial followed patients for 10 years with continued benefit [3]. AACE recommends reassessing fracture risk every 5 to 10 years, but stopping denosumab requires a transition plan. Oscar will reauthorize Prolia as long as clinical criteria remain met.

Patients receiving Prolia every 6 months should schedule the next injection within 7 days of the due date. Delaying beyond 8 weeks between doses may allow bone density loss. Contact your Oscar care team at least 30 days before your next injection to ensure reauthorization is in place.